EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

AOXIN Q & M DENTAL GRP LIMITED (1D4) fair value: what the stock is really worth

As of Oct 1, 2026: fair value of AOXIN Q & M DENTAL GRP LIMITED S$0.03, price S$0.17, upside -80.1%, quality 42 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · SG · ISIN SG1DF9000000

AQ Thin data Oct 1, 2026

AOXIN Q & M DENTAL GRP LIMITED

1D4 · SG

Weakest SetupStrongly overvalued and low quality.

!Fair value 0.0340 SGD · Strongly overvalued (−80.1%)
!Quality 42/100
!Expensive Growth (revenue 5y +5.1 %/yr)
!Thin margins · 2.8% net margin (TTM)
✓Low debt · generates free cash flow
!Trails peers (3/11)
!Narrow moat 20/100
!Evidence only low, so the estimate is less certain
!Weak on past: 5 out of 100
Watch AOXIN Q & M DENTAL GRP LIMITED for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

0.3150 SGD 0.0300 SGD Fair Value 0.0340 SGD Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.

How to read this chart

60‑month range 0.0300 SGD – 0.3150 SGD · fair‑value band 0.0255 SGD – 0.0340 SGD · the 0.1710 SGD price screens above the 0.0340 SGD fair value. Dashed = 300-day average. As of Oct 1, 2026.

Follow AOXIN Q & M DENTAL GRP in your weekly email

Every Wednesday you see whether AOXIN Q & M DENTAL GRP is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Aoxin Q & M Dental Group Limited, an investment holding company, provides private dental healthcare services in the People's Republic of China and Singapore. It operates through three segments: Primary Healthcare; Distribution of Dental Equipment and Supplies; and Laboratory Services.

Show more

Aoxin Q & M Dental Group Limited, an investment holding company, provides private dental healthcare services in the People's Republic of China and Singapore. It operates through three segments: Primary Healthcare; Distribution of Dental Equipment and Supplies; and Laboratory Services. It offers private dental services, such as stomatology and general dentistry, endodontics, orthodontics, periodontics, prosthodontics, dental implantology, oral and maxillofacial surgery, aesthetic dentistry, and paedodontics; and operates dental centers comprising dental polyclinics and dental hospitals in Liaoning Province. The company also distributes and sells dental equipment and supplies, such as dental chairs, ultrasound scanners, dental instruments, and materials and consumables to dental hospitals, clinics, distributors, and laboratories. In addition, it provides laboratory services, which includes the manufacturing of porcelain crown, bridges, and dentures; and leases medical equipment. Further, the company offers technical and investment consultancy services; and develops dental inlay technology, as well as involved in trading of medical and dental instruments and supplies. Aoxin Q & M Dental Group Limited was founded in 1997 and is based in Singapore.

Stock analysis

AOXIN Q & M DENTAL GRP LIMITED (1D4) currently trades at 0.1710 SGD, while our model-based Fair Value estimate is 0.0340 SGD, 80.1% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 0.0500 SGD per share, and 0 of the 24 models we run sit above the 0.1710 SGD price.

Bear case: the Multiples group reads lowest at 0.0300 SGD, and 24 of the 24 models stay below the price. Evidence for this calculation is low.

Scenario range: 0.0255 SGD (bear) to 0.0340 SGD (bull), the price of 0.1710 SGD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

AOXIN Q & M DENTAL GRP LIMITED reported revenue of 171M CNY in FY2025 versus 160M CNY in FY2021, a compound +1.7%/yr. Reported net income was 7.0M CNY in FY2025.

Key figures

Market cap 198M SGD (≈ $155M) · P/S ratio 1.20 · Net margin 4.1% · Return on equity 1.2% · Return on assets (EBIT) 2.1% · Operating margin 2.6% · Revenue (TTM) 165M CNY · Revenue growth (YoY) −11.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 46% below its 52-week high and 375% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −80%, 1D4 screens richer than that median.

Fair Value models

Bear 0.0255 SGD Fair Value 0.0340 SGD Bull 0.0340 SGD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF 0.0300 SGD 0.0300 SGD 0.0400 SGD 82
Growth DCF 0.0300 SGD 0.0300 SGD 0.0400 SGD 80
Owner Earnings 0.0600 SGD 0.1000 SGD 0.1600 SGD 75
All 24 models by family
DCF Models
FCF DCF 0.0300 SGD 0.0300 SGD 0.0400 SGD 82
Owner Earnings 0.0600 SGD 0.1000 SGD 0.1600 SGD 75
5Y Revenue Exit 0.0400 SGD 0.0500 SGD 0.0700 SGD 73
5Y EBITDA Exit 0.0500 SGD 0.0800 SGD 0.1400 SGD 73
5Y P/E Exit 0.0400 SGD 0.0600 SGD 0.0900 SGD 70
10Y Revenue Exit 0.0300 SGD 0.0500 SGD 0.0600 SGD 67
10Y EBITDA Exit 0.0400 SGD 0.0800 SGD 0.1400 SGD 65
10Y P/E Exit 0.0400 SGD 0.0500 SGD 0.0800 SGD 63
Earnings-Based
Graham-Dodd 0.0100 SGD 0.0500 SGD 0.0800 SGD 62
Lynch FV 0.0300 SGD 0.0400 SGD 0.0500 SGD 61
PEG = 1.0 0.0300 SGD 0.0400 SGD 0.0500 SGD 57
EPV 0.0300 SGD 0.0400 SGD 0.0400 SGD 74
Multiples
P/E Multiple 0.0200 SGD 0.0300 SGD 0.0300 SGD 63
P/S Multiple 0.0100 SGD 0.0200 SGD 0.0200 SGD 58
P/B Multiple 0.0100 SGD 0.0200 SGD 0.0200 SGD 55
EV/EBIT 0.0400 SGD 0.0500 SGD 0.0600 SGD 66
EV/EBITDA 0.0700 SGD 0.0800 SGD 0.0900 SGD 67
EV/Revenue 0.0400 SGD 0.0500 SGD 0.0500 SGD 54
Asset-Based
NCAV (Graham) 0.0300 SGD 0.0400 SGD 0.0600 SGD 54
Growth DCF
Growth DCF 0.0300 SGD 0.0300 SGD 0.0400 SGD 80
Rev-Margin DCF 0.0400 SGD 0.0500 SGD 0.0800 SGD 72
Economic Profit
Residual Income 0.0400 SGD 0.0300 SGD 0.0300 SGD 71
ROIC Compounder 0.0300 SGD 0.0400 SGD 0.0400 SGD 72
Growth Earnings
Growth-Adj P/E 0.0300 SGD 0.0500 SGD 0.0600 SGD 67

Open the full fair value analysis →

Notify me when 1D4 reaches fair value

Put 1D4 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 42/100

Of which business quality 45 · Market factors (momentum, volatility) 46

Profitability 31
Margins and returns on capital today
Quality Growth 48
Are margins and returns improving?
Cashflow 17
Earnings quality: real cash, not paper profit
Fin. Strength 89
Balance sheet, leverage, solvency risk
Investment 91
Disciplined investing over empire-building
Low Volatility 20
Calm price path (market factor)
Momentum 46
Price trend over the last 3–12 months (market factor)
52W Momentum 74
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 43/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−3.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.1%
Start year 2020 (pandemic). Over 10 years: +13.9% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+63.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−8.3% (2020) → 5.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

Growth Forecast

A lot of optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
more than +80 %
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.

1D4 screens overvalued: fair value 80% below the price. Compare with HCA Healthcare, Inc →

Compare AOXIN Q & M DENTAL GRP LIMITED with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 244 stocks

Beats the industry median on 2/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 42 · Bottom 25%
Fair Value upside −80.1% · Bottom 25%
Profitability
Return on equity (TTM) 1.2% · Below median
Return on assets 1.2% · Bottom 25%
Net margin (TTM) 2.8% · Below median
Operating margin (TTM) 2.6% · Bottom 25%
Growth and dividend
Revenue growth −11.8% · Bottom 25%

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 0.44× · Cheapest 25%
P/S (TTM) 0.94× · Cheaper than median
P/FCF 80.1× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 33
FUTURE (revenue growth)0 · sector 29
PAST (return on equity)5 · sector 31
HEALTH (low debt)100 · sector 89
DIVIDEND (yield)0 · sector 38

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $431.63 $597.97 +39%
Fresenius SE FRE €46.15 €34.49 −25%
Dr. Sulaiman Al Habib Medical Services Group 4013 225.00 SAR 109.45 SAR −51%
Tenet Healthcare Corporation THC $257.93 $274.35 +6%
IHH Healthcare Berhad, an investment holding company, 5225 8.03 MYR 4.87 MYR −39%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,889 ₹2,908 −67%
Encompass Health Corporation EHC $123.47 $94.47 −23%
Fresenius Medical Care AG FMS $22.27 $45.84 +106%
DaVita Inc DVA $178.07 $215.81 +21%
Aier Eye Hospital Group 300015 ¥7.91 ¥10.86 +37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

AOXIN Q & M DENTAL GRP LIMITED · Fair Value
0.0340 SGD −80%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "AOXIN Q & M DENTAL GRP LIMITED Fair Value". https://www.fairvalue-calculator.com/stock/1D4

Frequently asked questions

Is AOXIN Q & M DENTAL GRP LIMITED (1D4) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of 0.0340 SGD versus a price of 0.1710 SGD, about −80% upside (overvalued).
What is the fair value of 1D4?
Our model-based fair value for AOXIN Q & M DENTAL GRP LIMITED is 0.0340 SGD (as of Oct 1, 2026), built from audited fundamentals. The current price: 0.1710 SGD.
What is the quality score of 1D4?
AOXIN Q & M DENTAL GRP LIMITED has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for AOXIN Q & M DENTAL GRP LIMITED (1D4)?
Our model-based price target is the fair value of 0.0340 SGD (as of Oct 1, 2026) from 24 valuation models. Cautious scenario 0.0255 SGD, optimistic scenario 0.0340 SGD. It is a calculation from audited fundamentals, not an analyst target.
What is the AOXIN Q & M DENTAL GRP LIMITED stock forecast for 2026?
Our models put fair value at 0.0340 SGD, about −80% upside versus a price of 0.1710 SGD (overvalued). Cautious scenario 0.0255 SGD, optimistic scenario 0.0340 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of AOXIN Q & M DENTAL GRP LIMITED (1D4)?
AOXIN Q & M DENTAL GRP LIMITED reported trailing-twelve-month revenue of about 165M CNY (latest available figure, as of Oct 1, 2026).
What growth is priced into AOXIN Q & M DENTAL GRP LIMITED (1D4)?
For today's price to be fair in a discounted-cash-flow model, AOXIN Q & M DENTAL GRP LIMITED would have to grow free cash flow by more than 80 % per year for five years (discount rate 13.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.1 % per year. As of Oct 1, 2026.
What discount rate (WACC) does the fair value of 1D4 use?
Our models discount AOXIN Q & M DENTAL GRP LIMITED at 13.4 %: a base by market capitalisation (micro), damped by beta 1.29, country premium for Singapore. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For AOXIN Q & M DENTAL GRP LIMITED that is more than 80 % per year a year over ten years, using the same discount rate (13.4 %) and the same formula as our fair value.
How much growth has AOXIN Q & M DENTAL GRP LIMITED (1D4) delivered so far?
Over the past 5 years revenue at AOXIN Q & M DENTAL GRP LIMITED grew +5.1 % a year. The price currently implies more than 80 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of AOXIN Q & M DENTAL GRP LIMITED (1D4) growing?
The median revenue growth in the sector is +4.6 % a year. That is the yardstick for the growth priced into AOXIN Q & M DENTAL GRP LIMITED (more than 80 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of AOXIN Q & M DENTAL GRP LIMITED (1D4)?
The free-cash-flow yield on the price is 0.21 %: that much free cash flow AOXIN Q & M DENTAL GRP LIMITED produces per unit of market value. When it exceeds the discount rate of our models (13.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of AOXIN Q & M DENTAL GRP LIMITED (1D4)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AOXIN Q & M DENTAL GRP LIMITED it is 0.0340 SGD per share (as of Oct 1, 2026), against a price of 0.1710 SGD. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is AOXIN Q & M DENTAL GRP LIMITED stock overvalued or undervalued in 2026?
As of Oct 1, 2026, 1D4 trades above its calculated fair value: price 0.1710 SGD, fair value 0.0340 SGD, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1D4?
No. The price is what the market pays today (0.1710 SGD); the fair value is what the company's own numbers justify (0.0340 SGD). For AOXIN Q & M DENTAL GRP LIMITED the two are 0.1370 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is AOXIN Q & M DENTAL GRP LIMITED worth?
The market values AOXIN Q & M DENTAL GRP LIMITED at about 198M SGD (market capitalisation, as of Oct 1, 2026). Per share that is 0.1710 SGD; our models calculate a fair value of 0.0340 SGD per share.
What do the bullish and bearish scenarios say about 1D4?
Our models span a range for AOXIN Q & M DENTAL GRP LIMITED: cautious scenario 0.0255 SGD, base 0.0340 SGD, optimistic 0.0340 SGD per share (as of Oct 1, 2026, price 0.1710 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of AOXIN Q & M DENTAL GRP LIMITED (1D4)?
Balance-sheet figures for AOXIN Q & M DENTAL GRP LIMITED (as of Oct 1, 2026): return on equity 1.2%. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 1D4 from its 52-week high?
AOXIN Q & M DENTAL GRP LIMITED trades at 0.1710 SGD, about 46% below its 52-week high of 0.3150 SGD and 375% above the low of 0.0360 SGD (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of 0.0340 SGD is for.
Which stocks are comparable to AOXIN Q & M DENTAL GRP LIMITED?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is AOXIN Q & M DENTAL GRP LIMITED stock attractive at the current price?
The data as of Oct 1, 2026: price 0.1710 SGD, calculated fair value 0.0340 SGD (−80%), Quality Score 42/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1D4 calculated?
We run AOXIN Q & M DENTAL GRP LIMITED through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.0340 SGD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. AOXIN Q & M DENTAL GRP LIMITED itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of AOXIN Q & M DENTAL GRP LIMITED (1D4)?
The closing price on Oct 1, 2026 was 0.1710 SGD. Our model-based fair value is 0.0340 SGD, about −80% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with AOXIN Q & M DENTAL GRP LIMITED right now?
The price sits above even our optimistic bull case (0.0340 SGD). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of AOXIN Q & M DENTAL GRP LIMITED

How large is the market capitalisation of AOXIN Q & M DENTAL GRP LIMITED (1D4)?
The market capitalisation of AOXIN Q & M DENTAL GRP LIMITED is 198M SGD (≈ $155M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of AOXIN Q & M DENTAL GRP LIMITED (1D4)?
The price-to-sales ratio of AOXIN Q & M DENTAL GRP LIMITED is 1.20 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of AOXIN Q & M DENTAL GRP LIMITED (1D4)?
The net margin of AOXIN Q & M DENTAL GRP LIMITED is 4.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of AOXIN Q & M DENTAL GRP LIMITED (1D4)?
The return on equity (ROE) of AOXIN Q & M DENTAL GRP LIMITED is 1.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of AOXIN Q & M DENTAL GRP LIMITED (1D4)?
On an EBIT basis the return on assets of AOXIN Q & M DENTAL GRP LIMITED is 2.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of AOXIN Q & M DENTAL GRP LIMITED (1D4)?
The operating margin of AOXIN Q & M DENTAL GRP LIMITED is 2.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at AOXIN Q & M DENTAL GRP LIMITED (1D4)?
Revenue at AOXIN Q & M DENTAL GRP LIMITED is growing −11.8% versus a year earlier (3y avg +7.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at AOXIN Q & M DENTAL GRP LIMITED (1D4)?
Earnings per share at AOXIN Q & M DENTAL GRP LIMITED are growing −94.3% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch AOXIN Q & M DENTAL GRP LIMITED in the live analysis

One click puts AOXIN Q & M DENTAL GRP LIMITED on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.